Allergy Therapeutics plc (AIM: AGY) has pioneered an ultra-short course allergy treatment (typically acute hayfever), Pollinex Quattro, which in the financial year ending June 2019 year generated revenues in excess of £73m mostly in Europe.
The ability to deliver a disease-modifying outcome as opposed to simply symptomatic relief, with short/ultrashort course treatments significantly differentiates Pollinex Quattro from its competitors.
AGY has established a significant market share in the European market, achieving double-digit compound annual revenue growth over the past 18 years. AGY is seeking to roll out Pollinex Quattro in the US, which has an estimated US$2bn market. To date 15 clinical trials have been completed, including phase I, II & III.
As at 30 June 2020 AGY had a cash balance of £37m. The Group’s total bank loan debt was £3.8m.
To visit Allergy Therapeutics website, click here
Manuel Llobet (CEO)
Joined 2009. Previously CEO of International Operations of the Weinstein family’s group of companies.
Nick Wykeman (FD)
Ex Group Financial Controller of Skyepharma. Held same role at Quest International (part of ICI PLC)
Peter Jensen (NE Chairman)
21yrs with SmithKline Beecham. Previously NED of several listed businesses.
NED’s – Thomas Lander (25 yrs R&D in pharma), Stephen Smith (management accountant), Jeff Barton (VP licensing & acquisitions, Abbott), Scott Leinenweber VP of IR & Licensing & Acquisitions at Abbott), Mary Taverner (19yrs Director at Advance Medial Solutions)
AIM-listed Allergy Therapeutics (LON: AGY) announces today further investment in its virus-like particle (‘VLP’) technology platform for treatments beyond allergy …
Allergy Therapeutics secures virus-like particle (“VLP”) technology platform to broaden vaccine pipeline through licensing agreements with Saiba AG and DeepVax …
Strong 2020 performance despite COVID-19 challenge Earnings above market expectations Net revenue of £78.2million representing 6% annual growth Strong cash …
Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today provides a trading update …
Allergy Therapeutics welcomes European Academy of Allergy and Clinical Immunology review paper exploring adjuvants and formulations in allergy immunotherapies Review …
Record level of operating profit pre R&D supported by strong sales Strong cash position with Grass MATA MPL Phase III …
|Cost of Sales||(18,379)||(17,013)|
|Profit/ (Loss) for the period||3,467||(7,533)|
|Cash & cash equivalents||27,440||15,533|
ALK (OMX: ALKB)
Grass & ragweed allergy treatment
Stallergenes (EURO: STAGR)
Grass allergy treatment
ALK Abello (CPH: ALK-B)
Research-driven pharma, focused on allergies
DBV Technologies (EPA: DBV)
Biopharmaceutical company focused on food allergies
Manuel Llobet – 0.55%
Stephen Smith – 0.13%
Peter Jensen – 0.03%
Nick Wykeman – 0.03%
Weinstein A ESQ – 37.82%
Southern Fox Investments Ltd – 22.69%
Odey Asset Management – 6.46%
River & Mercantile – 5.54%
Blackrock – 5.33%
Invesco – 4.15%
GlaxoSmithKlein PLC – 1.59%
“…the global vaccine market, in its entirety, has quadrupled in value since 2000 with the World Health Organisation estimating market growth to almost $100bn by 2025.” (Panmure Gordon note, June 2015)
“In the US, it is estimated over 80m people suffer from Allergic Rhinitis (AR), albeit with diagnosis rates which remain low at 31%.” (Panmure Gordon note, June 2015)
Investors Chronicle (Sep 2019): “Allergy looks to future trials”
“Shares in Allergy Therapeutics (AGY) tumbled earlier this year after the unexpected failure of its birch allergy treatment at the third phase of trials. Remaining “in dialogue” with German regulators, the group has shifted its attention instead to its grass allergy vaccine, due to start its Phase III trial in autumn next year. Success here would be one of the last hurdles before being able to tap into a US market estimated to be worth $2bn (£1.6bn).”
Panmure Gordon (House Broker, Jan 2020)
“The update is in-line with board expectations, speaking to ‘strong earnings’ and continued growth in market share. This is underpinned by H1 revenue growth of +9% constant currency (+8% reported) to £50.5m (2018: £46.7m). Cash at the end of December 2019 was £39.7m (31 December 2018: £31.6m) which will fund the Grass MATA MPL Phase III Trial, planned and on track to start screening for the first stage of the study during summer 2020.”